Conference Call with Granules India Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Granules India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations of Q4FY25 stood at Rs 11,974 million, a growth of 2% YoY, Sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility with ongoing USFDA remediation activities. ROCE is at 16.6% as compared to 16.5% YoY Net debt stood at Rs 7,061 million, a reduction of Rs 1,360 million and Net debt to EBITDA at 0.75x EBITDA slightly declined by 1%, from Rs 2,557 million to Rs 2,524 million. EBITDA Margin dipped from 22% to 21%. PAT grew 17%, from Rs 1,296 million to Rs 1,520 million. FY25 Financial Highlights: Revenue from Operations declined by 1%, from Rs 45,064 million to Rs 44,816 million. EBITDA increased 10%, from Rs 8,560 million to Rs 9,452 million. EBITDA Margin expanded from 19% to 21%. PAT surged 24%, from Rs 4,053 million to Rs 5,015 million. Commenting on the results, Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India said, “We are pleased to report a resilient bottom line and cash flow performance this year, despite sales remaining steady. This was achieved with a profitable Formulations growth of 18%, even though we proactively paused Gagillapur’s production operations in Sep-24 for more than a month to re-assess the risks and undertake necessary USFDA remediation activities. Productivity of Gagillapur facility has been lower in H2 FY25 with ongoing remediation activities. Our strong financial performance reflects the success of our strategic initiatives, particularly our focus on enhancing our product mix by prioritizing highmargin offerings and expanding our portfolio of non-legacy molecules. This reflects the strength and adaptability of our business model, and our unwavering commitment”. Result PDF